Differential influences of ethanol on early exposure to racemic methylphenidate compared with dexmethylphenidate in humans

Drug Metabolism and Disposition

Volumn 41, Issue 1, 2013, Pages 197-205

  Patrick, Kennerly S ^a   Straughn, Arthur B ^b   Reeves III, Owen T ^a   Bernstein, Hilary ^c   Bell, Guinevere H ^a   Anderson, Erica R ^a   Malcolm, Robert J ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CARBOXYLESTERASE; CARBOXYLESTERASE 1; DEXMETHYLPHENIDATE; METHYLPHENIDATE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; COMPETITIVE INHIBITION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG STRUCTURE; ENANTIOSELECTIVITY; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME SUBSTRATE; FEMALE; HEART HEMODYNAMICS; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; SEX DIFFERENCE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AREA UNDER CURVE; CARBOXYLESTERASE; ESTERIFICATION; ETHANOL; FEMALE; HEMODYNAMICS; HUMANS; MALE; METHYLPHENIDATE; STEREOISOMERISM; YOUNG ADULT;

EID: 84871536061     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.048595     Document Type: Article

References (45)

1. Aoyama T, Sasaki T, Kotaki H, Sawada Y, Sudoh Y, Honda Y, and Iga T (1994) Pharmacokinetics and pharmacodynamics of (+)-threo-methylphenidate enantiomer in patients with hypersomnia. Clin Pharmacol Ther 55:270-276.
2. Barrett SP, Darredeau C, Bordy LE, and Pihl RO (2005) Characteristics of methylphenidate misuse in a university student sample. Can J Psychiatry 50:457-461.
3. Bourland JA, Martin DK, and Mayersohn M (1997) Carboxylesterase-mediated transesterification of meperidine (Demerol) and methylphenidate (Ritalin) in the presence of [2H6]ethanol: preliminary in vitro findings using a rat liver preparation. J Pharm Sci 86:1494-1496.
4. Chen ML, Shah VP, Ganes D, Midha KK, Caro J, and Nambiar PRocci ML, Jr, Thombre AG, Abrahamsson B, and Conner D, et al. (2010) Challenges and opportunities in establishing scientific and regulatory standards for assuring therapeutic equivalence of modified-release products: workshop summary report. Eur J Pharm Sci 40:148-153.
5. Darredeau C, Barrett SP, Jardin B, and Pihl RO (2007) Patterns and predictors of medication compliance, diversion, and misuse in adult prescribed methylphenidate users. Hum Psychopharmacol 22:529-536.
6. Farré M, de la Torre R, González ML, Terán MT, Roset PN, Menoyo E, and Camí J (1997) Cocaine and alcohol interactions in humans: neuroendocrine effects and cocaethylene metabolism. J Pharmacol Exp Ther 283:164-176.
7. Hedaya MA and Pan WJ (1996) Cocaine and alcohol interactions in naive and alcohol-pretreated rats. Drug Metab Dispos 24:807-812.
8. Herbst ED, Harris DS, Everhart ET, Mendelson J, Jacob P, and Jones RT (2011) Cocaethylene formation following ethanol and cocaine administration by different routes. Exp Clin Psychopharmacol 19:95-104.
9. Koehm M, Kauert GF, and Toennes SW (2010) Influence of ethanol on the pharmacokinetics of methylphenidate's metabolites ritalinic acid and ethylphenidate. Arzneimittelforschung 60:238-244.
10. Kollins SH, Rush CR, Pazzaglia PJ, and Ali JA (1998) Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp Clin Psychopharmacol 6:367-374.
11. LeVasseur NL, Zhu HJ, Markowitz JS, DeVane CL, and Patrick KS (2008) Enantiospecific gas chromatographic-mass spectrometric analysis of urinary methylphenidate: implications for phenotyping. J Chromatogr B Analyt Technol Biomed Life Sci 862:140-149.
12. Levin FR and Kleber HD (1995) Attention-deficit hyperactivity disorder and substance abuse: relationships and implications for treatment. Harv Rev Psychiatry 2:246-258.
13. Markowitz JS, Logan BK, Diamond F, and Patrick KS (1999) Detection of the novel metabolite ethylphenidate after methylphenidate overdose with alcohol coingestion. J Clin Psychopharmacol 19:362-366.
14. Markowitz JS and Patrick KS (2008) Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? J Clin Psychopharmacol 28(3, Suppl 2)S54-S61.
15. Metzler CM (1991) Sample sizes for bioequivalence studies. Stat Med 10:961-969, discussion 969-970.
16. Modi NB, Wang B, Noveck RJ, and Gupta SK (2000) Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system. J Clin Pharmacol 40:1141-1149.
17. Novak SP, Kroutil LA, Williams RL, and Van Brunt DL (2007) The nonmedical use of prescription ADHD medications: results from a national Internet panel. Subst Abuse Treat Prev Policy 2:32-48.
18. Parker RB and Laizure SC (2010) The effect of ethanol on oral cocaine pharmacokinetics reveals an unrecognized class of ethanol-mediated drug interactions. Drug Metab Dispos 38:317-322.
19. Patrick KS, Kilts CD, and Breese GR (1981) Synthesis and pharmacology of hydroxylated metabolites of methylphenidate. J Med Chem 24:1237-1240.
20. Patrick KS, Straughn AB, Minhinnett RR, Yeatts SD, Herrin AE, DeVane CL, Malcolm R, Janis GC, and Markowitz JS (2007) Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 81:346-353.
21. Patrick KS, Williard RL, VanWert AL, Dowd JJ, Oatis JE, Jr, and Middaugh LD (2005) Synthesis and pharmacology of ethylphenidate enantiomers: the human transesterification metabolite of methylphenidate and ethanol. J Med Chem 48:2876-2881.
22. Perez-Reyes M (1994) The order of drug administration: its effects on the interaction between cocaine and ethanol. Life Sci 55:541-550.
23. Redalieu E, Bartlett MF, Waldes LM, Darrow WR, Egger H, and Wagner WE (1982) A study of methylphenidate in man with respect to its major metabolite. Drug Metab Dispos 10:708-709.
24. Roberts SM, Harbison RD, and James RC (1993) Inhibition by ethanol of the metabolism of cocaine to benzoylecgonine and ecgonine methyl ester in mouse and human liver. Drug Metab Dispos 21:537-541.
25. Roberts SM, Phillips DL, and Tebbett IR (1995) Increased blood and brain cocaine concentrations with ethanol cotreatment in mice. Drug Metab Dispos 23:664-666.
26. Rowland M and Tozer T (1989) Clinical Pharmacokinetics: Concepts and Applications, Lea and Febiger, London.
27. Scharman EJ, Erdman AR, Cobaugh DJ, Olson KR, Woolf AD, Caravati EM, Chyka PA, Booze LL, Manoguerra AS, and Nelson LS, et al.; American Association of Poison Control Centers (2007) Methylphenidate poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 45:737-752.
28. Spaak J, Merlocco AC, Soleas GJ, Tomlinson G, Morris BL, Picton P, Notarius CF, Chan CT, and Floras JS (2008) Dose-related effects of red wine and alcohol on hemodynamics, sympathetic nerve activity, and arterial diameter. Am J Physiol Heart Circ Physiol 294:H605-H612.
29. Spencer TJ, Biederman J, Ciccone PE, Madras BK, Dougherty DD, Bonab AA, Livni E, Parasrampuria DA, and Fischman AJ (2006) PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry 163:387-395.
30. Spencer TJ, Biederman J, Martin JM, Moorehead TM, Mirto T, Clarke A, Batchelder H, and Faraone SV (2012) Importance of pharmacokinetic profile and timing of coadministration of short- and long-acting formulations of methylphenidate on patterns of subjective responses and abuse potential. Postgrad Med 124:166-173.
31. Srinivas NR, Hubbard JW, Korchinski ED, and Midha KK (1993) Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans. Pharm Res 10:14-21.
32. Srinivas NR, Hubbard JW, Quinn D, and Midha KK (1992) Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder. Clin Pharmacol Ther 52:561-568.
33. Stoops WW, Glaser PE, Fillmore MT, and Rush CR (2004) Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans. J Psychopharmacol 18:534-543.
34. Sun Z, Murry DJ, Sanghani SP, Davis WI, Kedishvili NY, Zou Q, Hurley TD, and Bosron WF (2004) Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J Pharmacol Exp Ther 310:469-476.
35. Swanson JM and Volkow ND (2003) Serum and brain concentrations of methylphenidate: implications for use and abuse. Neurosci Biobehav Rev 27:615-621.
36. Teter CJ, McCabe SE, Boyd CJ, and Guthrie SK (2003) Illicit methylphenidate use in an undergraduate student sample: prevalence and risk factors. Pharmacotherapy 23:609-617.
37. Tuerck D, Wang Y, Maboudian M, Wang Y, Sedek G, Pommier F, and Appel-Dingemanse S (2007) Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethylphenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man. Int J Clin Pharmacol Ther 45:662-668.
38. Volkow ND and Swanson JM (2003) Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 160:1909-1918.
39. Wigal S, Swanson JM, Feifel D, Sangal RB, Elia J, Casat CD, Zeldis JB, and Conners CK (2004) A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 43:1406-1414.
40. Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, Utzinger L, and Fusillo S (2008) Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 47:21-31.
41. Williard RL, Middaugh LD, Zhu HJ, and Patrick KS (2007) Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity. Behav Pharmacol 18:39-51.
42. Winer B (1962) Statistical Principles in Experimental Design, 1st ed, McGraw-Hill, New York.
43. Zhu HJ, Appel DI, Jiang Y, andMarkowitz JS (2009) Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver. Drug Metab Dispos 37:1819-1825.
44. Zhu HJ, Patrick KS, and Markowitz JS (2011) Enantiospecific determination of DL-methylphenidate and DL-ethylphenidate in plasma by liquid chromatography-tandem mass spectrometry: application to human ethanol interactions. J Chromatogr B Analyt Technol Biomed Life Sci 879:783-788.
45. Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL, Malcolm R, Johnson JA, Youngblood GL, and Sweet DH, et al. (2008) Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet 82:1241-1248.